FDA Approves Pavblu (aflibercept) for Neovascular AMD, RVO, DME, and DR

Pavblu is a vascular endothelial growth factor (VEGF) inhibitor. It binds to VEGF and inhibits its activity, reducing angiogenesis and vascular permeability.

Pavblu is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Pavblu is administered by intravitreal injection only by a qualified physician. For wet AMD: 2 mg (0.05 mL of 40 mg/mL solution) every 4 weeks for the first 3 months, then 2 mg every 8 weeks. Some patients may need monthly dosing after 12 weeks. For RVO: 2 mg every 4 weeks. For DME and DR: 2 mg every 4 weeks for the first 5 injections, then 2 mg every 8 weeks. Some patients may need monthly dosing after 20 weeks. For wet AMD, patients may also be treated every 12 weeks after one year of effective therapy, though this is less effective.

Trial data not available in label.

Not reported in label.

Pavblu is a VEGF inhibitor for multiple retinal conditions. It offers an alternative to other anti-VEGF agents. Dosing flexibility allows for extended intervals in some patients.